Claritev (NYSE:CTEV) SVP Nutter Carol Purchases 875 Shares

Claritev (NYSE:CTEV) SVP Nutter Carol bought 875 shares of the stock in a transaction that occurred on Tuesday, June 9th. The shares were purchased at an average cost of $28.41 per share, for a total transaction of $24,858.75. Following the completion of the acquisition, the senior vice president owned 46,941 shares of the company’s stock, valued at $1,333,593.81. This trade represents a 1.90% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Claritev Trading Up 4.2%

NYSE:CTEV traded up $1.20 during mid-day trading on Wednesday, reaching $29.55. 82,852 shares of the stock were exchanged, compared to its average volume of 182,812. The business has a fifty day moving average price of $22.08 and a 200 day moving average price of $26.85. The firm has a market capitalization of $503.83 million, a PE ratio of -1.71 and a beta of 0.77. Claritev has a 1-year low of $11.50 and a 1-year high of $74.07.

Hedge Funds Weigh In On Claritev

Institutional investors and hedge funds have recently bought and sold shares of the business. Oak Hill Advisors LP purchased a new position in Claritev during the 3rd quarter valued at about $4,871,000. H&F Corporate Investors VIII Ltd. purchased a new position in Claritev during the 3rd quarter valued at about $285,988,000. Topline Capital Management LLC purchased a new position in Claritev during the 3rd quarter valued at about $10,711,000. Citigroup Inc. purchased a new position in Claritev during the 3rd quarter valued at about $2,025,000. Finally, Beach Point Capital Management LP grew its stake in Claritev by 77.4% during the 4th quarter. Beach Point Capital Management LP now owns 755,002 shares of the company’s stock valued at $32,276,000 after acquiring an additional 329,424 shares in the last quarter. Hedge funds and other institutional investors own 87.15% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Citigroup reaffirmed a “buy” rating on shares of Claritev in a report on Wednesday, May 13th. Guggenheim reissued a “buy” rating on shares of Claritev in a research note on Tuesday, February 24th. Piper Sandler set a $61.00 price target on Claritev in a research note on Wednesday, June 3rd. Barclays began coverage on Claritev in a research note on Friday, April 24th. They issued an “overweight” rating and a $28.00 price target on the stock. Finally, Wells Fargo & Company dropped their price target on Claritev from $30.00 to $22.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 19th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $33.67.

About Claritev

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.